Nan Huo

570 total citations
8 papers, 302 citations indexed

About

Nan Huo is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Nan Huo has authored 8 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Nan Huo's work include RNA modifications and cancer (2 papers), Cancer-related molecular mechanisms research (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Nan Huo is often cited by papers focused on RNA modifications and cancer (2 papers), Cancer-related molecular mechanisms research (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Nan Huo collaborates with scholars based in China and United States. Nan Huo's co-authors include Xiaofeng Kang, Lei Kang, Xiaojie Xu, Xiang Zhu, Chunyuan Xue, Zhong Chu, Rui Cong, Luyuan Ma, Weibo Cai and Hanxiao Liu and has published in prestigious journals such as Advanced Science, Molecular Therapy and Cell Death and Disease.

In The Last Decade

Nan Huo

8 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nan Huo China 8 190 126 76 50 47 8 302
Silvia Esposito Italy 9 153 0.8× 77 0.6× 123 1.6× 20 0.4× 81 1.7× 9 296
Veronica Bonasera Italy 5 152 0.8× 44 0.3× 228 3.0× 66 1.3× 73 1.6× 5 375
Noga Bloushtain-Qimron United States 7 258 1.4× 130 1.0× 137 1.8× 9 0.2× 49 1.0× 8 375
Zhang Cao China 11 268 1.4× 156 1.2× 87 1.1× 12 0.2× 20 0.4× 20 369
Zu-Shun Chen China 7 112 0.6× 185 1.5× 165 2.2× 26 0.5× 64 1.4× 10 356
Hanna Nyström Sweden 10 108 0.6× 103 0.8× 154 2.0× 20 0.4× 38 0.8× 18 275
Katriana Nugent United States 8 297 1.6× 95 0.8× 202 2.7× 17 0.3× 61 1.3× 14 460
Ron Korn United States 8 104 0.5× 83 0.7× 206 2.7× 71 1.4× 68 1.4× 26 350
Seung-Pil Shin South Korea 10 198 1.0× 79 0.6× 113 1.5× 15 0.3× 20 0.4× 18 333
Marie‐Emmanuelle Legrier France 6 95 0.5× 59 0.5× 90 1.2× 18 0.4× 76 1.6× 9 220

Countries citing papers authored by Nan Huo

Since Specialization
Citations

This map shows the geographic impact of Nan Huo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Huo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Huo more than expected).

Fields of papers citing papers by Nan Huo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nan Huo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Huo. The network helps show where Nan Huo may publish in the future.

Co-authorship network of co-authors of Nan Huo

This figure shows the co-authorship network connecting the top 25 collaborators of Nan Huo. A scholar is included among the top collaborators of Nan Huo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nan Huo. Nan Huo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Zhu, Xiang, Chunyuan Xue, Xiaofeng Kang, et al.. (2022). DNMT3B-mediated FAM111B methylation promotes papillary thyroid tumor glycolysis, growth and metastasis. International Journal of Biological Sciences. 18(11). 4372–4387. 34 indexed citations
2.
Huo, Nan, Rui Cong, Wenchao Li, et al.. (2021). STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis. Cell Death and Disease. 12(9). 799–799. 69 indexed citations
3.
Han, Shulan, Wenyan Ma, Dawei Jiang, et al.. (2021). Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine. Journal of Nanobiotechnology. 19(1). 394–394. 31 indexed citations
4.
Kang, Lei, Cuicui Li, Qi Yang, et al.. (2021). 64Cu-labeled daratumumab F(ab′)2 fragment enables early visualization of CD38-positive lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 49(5). 1470–1481. 19 indexed citations
5.
Chu, Zhong, Nan Huo, Xiang Zhu, et al.. (2021). FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect. Molecular Therapy. 29(9). 2737–2753. 88 indexed citations
6.
Li, Cuicui, Lei Kang, Kevin Fan, et al.. (2021). ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models. Bioconjugate Chemistry. 32(7). 1306–1314. 21 indexed citations
7.
Kang, Lei, Cuicui Li, Zachary T. Rosenkrans, et al.. (2021). CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab. Advanced Science. 8(10). 2001879–2001879. 33 indexed citations
8.
Zhu, Xiang, An Xu, Nan Huo, et al.. (2020). <p>ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway</p>. OncoTargets and Therapy. Volume 13. 10515–10523. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026